May 16th 2025
A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
Healthcare Costs and Nonadherence Among Chronic Opioid Users
Healthcare costs are elevated for patients on chronic opioid therapy; nonadherence to the opioid regimen, based on urine drug monitoring results, further increases costs.
Read More